Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2022-11-30 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司第二届董事会2022年第五次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of 圣湘生物科技股份有限公司 (Shengxiang Bio-tech Co., Ltd.). It details the meeting date, attendance, and specific agenda items approved by the board, such as adjustments to a stock incentive plan, approval of stock vesting conditions, cancellation of unvested restricted stock, and project investment delays. The document does not contain financial statements or detailed financial data but rather reports on board decisions and approvals. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board of directors or senior management. The document length is 2043 characters, which is relatively short and consistent with a board meeting resolution announcement rather than a full report. Therefore, the appropriate classification is MANG with high confidence.
2022-11-30 Chinese
西部证券股份有限公司关于圣湘生物科技股份有限公司差异化权益分派事项的核查意见
Transaction in Own Shares Classification · 95% confidence The document is a verification opinion from a sponsoring institution regarding a differentiated equity distribution matter related to a company's share repurchase and dividend distribution. It discusses the company's share repurchase plans, the impact on dividend distribution, and the calculation of dividend amounts and ex-dividend prices. The document is not a full financial report but rather a formal opinion or verification related to a specific corporate action (share repurchase and dividend distribution). It does not contain comprehensive financial statements or earnings data. The content aligns with a report related to share repurchase activities and their impact on equity distribution, which fits the category of Transaction in Own Shares (POS). The document length is short (2286 characters), and it is not merely an announcement of a report but a detailed verification opinion. Therefore, the best classification is POS.
2022-11-22 Chinese
圣湘生物科技股份有限公司2022年季度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is a detailed announcement regarding the implementation of a quarterly dividend distribution for the year 2022 by the company 圣湘生物科技股份有限公司. It includes specifics on dividend amounts, relevant dates (record date, ex-dividend date, payment date), shareholder meeting approval, tax implications, and distribution methods. The document is not a full financial report but a formal notice about dividend payment details. It matches the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and related shareholder information. The document length is 3209 characters, which is consistent with a detailed dividend announcement rather than a full annual or quarterly report.
2022-11-22 Chinese
上海信公轶禾企业管理咨询有限公司关于圣湘生物科技股份有限公司2021年限制性股票激励计划预留授予相关事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an independent financial advisor report related to the 2021 restricted stock incentive plan of 圣湘生物科技股份有限公司 (Shengxiang Bio-technology Co., Ltd.). It details the approval procedures, reserved grant conditions, and the advisor's verification opinions on the stock incentive plan. The content focuses on the stock incentive plan's reserved grant matters, approval, and compliance with relevant laws and regulations. It is not a general annual report, earnings release, or management discussion but a specialized advisory report on a capital incentive plan. This fits the category of Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes through stock incentives. The document length (7433 characters) and detailed content confirm it is the report itself, not just an announcement. Therefore, the classification is CAP with high confidence.
2022-11-11 Chinese
圣湘生物科技股份有限公司关于调整2021年限制性股票激励计划授予数量的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from 圣湘生物科技股份有限公司 regarding the adjustment of the 2021 restricted stock incentive plan grant quantity. It details board and supervisory meetings, approvals, and legal opinions related to the adjustment of stock incentive quantities. The content focuses on corporate governance and stock incentive plan adjustments rather than financial results, earnings, or audit information. It is not a full annual or interim report, nor is it a call transcript or earnings release. It is also not a proxy solicitation or voting results announcement. The document is a regulatory announcement about management decisions on stock incentives, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories and is a formal disclosure of corporate governance actions related to stock incentives.
2022-11-11 Chinese
圣湘生物科技股份有限公司第二届董事会2022年第四次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the company's board of directors regarding resolutions passed at a specific board meeting. It details decisions about adjustments to a restricted stock incentive plan and the granting of reserved restricted stock to incentive recipients. The document includes voting results and references to related announcements on the stock exchange website. It does not contain financial statements, audit information, or detailed financial performance data. It is not a full report but an announcement of board decisions related to management and governance matters. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board resolutions, not a report or presentation.
2022-11-11 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.